ACTUATE THERAPEUTICS, INC. Operating Income (Loss) in USD from Q2 2023 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Actuate Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2023 to Q3 2025.
  • Actuate Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$5.47M, a 1.47% decline year-over-year.
  • Actuate Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$24.4M.
  • Actuate Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$25.2M, a 0.75% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

ACTUATE THERAPEUTICS, INC. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$24.4M -$5.47M -$79.5K -1.47% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 -$24.3M -$5.97M -$533K -9.81% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 -$23.8M -$6.37M +$1.41M +18.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q4 2024 -$25.2M -$6.56M Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 -$5.39M +$1.08M +16.7% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 -$5.44M +$149K +2.67% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 -$7.77M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q3 2023 -$6.48M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$5.58M Apr 1, 2023 Jun 30, 2023 10-Q 2024-09-24

ACTUATE THERAPEUTICS, INC. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$25.2M -$187K -0.75% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 -$25M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.